{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:51:24Z","timestamp":1793195484337,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.omtm.2019.11.018","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T20:16:05Z","timestamp":1574972165000},"page":"136-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"special_numbering":"C","title":["Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials"],"prefix":"10.1016","volume":"16","author":[{"given":"Seshu","family":"Tyagarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.11.018_bib1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.omtm.2019.11.018_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T\u00a0cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.11.018_bib3","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T\u00a0cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 2","key":"10.1016\/j.omtm.2019.11.018_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)\u2014an interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.omtm.2019.11.018_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib8","series-title":"Kymriah. Tisagenlecleucel","author":"Novartis Pharmaceuticals Corporation","year":"2018"},{"key":"10.1016\/j.omtm.2019.11.018_bib9","series-title":"Kymriah. Tisagenlecleucel","author":"Novartis Europharm Limited","year":"2018"},{"key":"10.1016\/j.omtm.2019.11.018_bib10","series-title":"Yescarta. Axicabtagene ciloleucel","year":"2017"},{"key":"10.1016\/j.omtm.2019.11.018_bib11","series-title":"Yescarta. Axicabtagene ciloleucel","year":"2019"},{"key":"10.1016\/j.omtm.2019.11.018_bib12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe","volume":"2","author":"Buechner","year":"2018","journal-title":"Hemasphere"},{"key":"10.1016\/j.omtm.2019.11.018_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.11.018_bib14","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy","volume":"179","author":"Zhang","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2019.11.018_bib15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.11.018_bib16","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2019.11.018_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T\u00a0cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib19","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.11.018_bib21","unstructured":"(2017). Tisagenlecleucel (CTL019) FDA Advisory Committee Briefing Document. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM566168.pdf."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:22:55Z","timestamp":1762420975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119301433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":21,"alternative-id":["S2329050119301433"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.11.018","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors.","name":"copyright","label":"Copyright"}]}}